Chene G, Caloone J, Moret S, Le Bail-Carval K, Chabert P, Beaufils E, Mellier G, Lamblin G
Département de Gynécologie, Hôpital Femme Mère Enfants, HCL, CHU Lyon Est, 59, boulevard Pinel, 69677 Bron, France; Université Claude Bernard Lyon 1, EMR 3738, 69000 Lyon, France.
Département de Gynécologie, Hôpital Femme Mère Enfants, HCL, CHU Lyon Est, 59, boulevard Pinel, 69677 Bron, France.
Gynecol Obstet Fertil. 2016 Feb;44(2):106-12. doi: 10.1016/j.gyobfe.2016.01.001. Epub 2016 Feb 3.
Epidemiological studies have shown a relationship between endometriosis and clear cell/endometrioid ovarian cancers (named "Endometriosis Associated Ovarian Cancer" or EAOC). The recent discovery of signaling pathways (especially the SWI/SNF and PI3K/AKT/mTOR pathways) that linked endometriosis and EAOC could lead to the development of specific biomarkers as ARID1A to screen benign to premalignant endometriosis and to new targeted treatment. Moreover, the better understanding of the pathogenesis of the epithelial ovarian cancer arising from the Fallopian tube could allow new early prevention strategies that will be described in this review.
流行病学研究表明,子宫内膜异位症与透明细胞/子宫内膜样卵巢癌(称为“子宫内膜异位症相关卵巢癌”或EAOC)之间存在关联。最近发现的连接子宫内膜异位症和EAOC的信号通路(尤其是SWI/SNF和PI3K/AKT/mTOR通路)可能会导致开发出特定的生物标志物,如ARID1A,用于筛查良性至癌前子宫内膜异位症,并促成新的靶向治疗。此外,对输卵管上皮性卵巢癌发病机制的更好理解可能会带来新的早期预防策略,本文将对此进行阐述。